((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
The US health regulator has approved the use of Dupixent, the flagship drug of Regeneron REGN.O and Sanofi SASY.PA, to treat allergic inflammation of the esophagus in children aged 1 to 11, announced the businesses Thursday.